Prediagnostic antibody responses to fusobacterium nucleatum proteins are not associated with risk of colorectal cancer in a large U.S. Consortium

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The association between prediagnostic antibody responses to Fusobacterium nucleatum (F. nucleatum) and subsequent risk of colorectal cancer is not established. Methods: We conducted a nested case-control study of 8,126 participants in a consortium of 10 prospective cohorts in the United States. Results: Higher seroprevalence of any F. nucleatum antibody was observed among non-White participants (51.1%) compared with White participants (31.2%). We did not find any statistically significant association between seropositivity to any of the eight F. nucleatum proteins and colorectal cancer risk. Conclusions: Prediagnostic antibody responses to F. nucleatum proteins were not associated with the risk of colorectal cancer. Impact: Future studies may consider a more specific detection of the immunoglobulin isotypes or focus on examining F. nucleatum in stool or tissue samples.

Cite

CITATION STYLE

APA

Lo, C. H., Blot, W. J., Teras, L. R., Visvanathan, K., Le Marchand, L., Haiman, C. A., … Song, M. (2021). Prediagnostic antibody responses to fusobacterium nucleatum proteins are not associated with risk of colorectal cancer in a large U.S. Consortium. Cancer Epidemiology Biomarkers and Prevention, 30(6), 1279–1282. https://doi.org/10.1158/1055-9965.EPI-20-1471

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free